Big Money’s Pro-Exact Sciences Corp (NASDAQ:EXAS) Sentiment In Q4 2018, now at 0.8

Exact Sciences Corporation (NASDAQ:EXAS) Corporate Logo

Exact Sciences Corp’s Sentiment

In Q4 2018 Exact Sciences Corp (NASDAQ:EXAS) big money sentiment decreased to 0.8, according to SEC filings. That’s down -0.35, from 2018Q3’s 1.15. 121 investment professionals increased and opened new holdings, while 152 decreased and sold equity positions in Exact Sciences Corp so the sentiment has dropped. These funds own 105.85 million shares, that’s down from 106.63 million shares in 2018Q3. Funds holding Exact Sciences Corp in top 10 increased from 6 to 9 for an increase of 3. 47 Investors Sold All; 105 Reduced Holdings; 69 increased stakes while 52 investment professionals bought stakes.

Significant Exact Sciences Corp Shareholders

Zevenbergen Capital Investments Llc owns 2.16 million shares in Exact Sciences Corp as of Q4 2018. Exact Sciences Corp’s shareholder Newtyn Management Llc owns 468,828 shares as of Q4 2018. R.H. Dinel Investment Counsel Inc. reported 64,900 shares. Green Valley Investors Llc revealed 1.04 million shares position in Exact Sciences Corp. The Pennsylvania-based fund Biondo Investment Advisors Llc looks positive on Exact Sciences Corp, possessing 159,325 shares.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States.The firm is valued at $12.09 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer.Currently it has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Ticker’s shares touched $96.15 during the last trading session after 1.43% change.Exact Sciences Corporation has volume of 1.20M shares. Since March 15, 2018 EXAS has risen 103.11% and is uptrending. EXAS outperformed the S&P500 by 98.74%.

Exact Sciences Corporation (NASDAQ:EXAS)’s earnings release is awaited by WallStreet on April, 25, according to Zacks. This year’s earnings per share analyst estimate is awaited to be $-0.64. That is 93.94 % down compareed to $-0.33 earnings per share for last year. After $-0.44 earnings per share was reported last quarter, analysts now see negative EPS growth of 45.45 % for Exact Sciences Corporation.

Earnest Prtn accumulated 0% or 64 shs. 101 were accumulated by Oppenheimer Asset Management. Hodges Mngmt accumulated 215,500 shs. Allstate has invested 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Adage Capital Prtn Gp Ltd reported 0.02% of its capital in Exact Sciences Corporation (NASDAQ:EXAS). Massmutual Tru Fsb Adv stated it has 0% of its capital in Exact Sciences Corporation (NASDAQ:EXAS). The Utah-based Utah Retirement has invested 0.03% in Exact Sciences Corporation (NASDAQ:EXAS). Advisory Svcs Ntwk Limited Liability Corporation has 0.03% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 4,912 shs. Bailard has invested 0.02% of its capital in Exact Sciences Corporation (NASDAQ:EXAS). Trexquant Inv L P holds 0.1% or 26,593 shs. Howe And Rusling has 20 shs for 0% of their capital. Rh Dinel Invest Counsel Inc invested in 4.6% or 64,900 shs. Bessemer Group stated it has 1,103 shs. Schroder Invest Mngmt Gp reported 5,926 shs. Nine Masts Limited has invested 0.03% of its capital in Exact Sciences Corporation (NASDAQ:EXAS).

Exact Sciences Corporation registered $58.02 million net activity with 0 insider purchases and 8 sales since September 30, 2018. On Monday, October 8 LIDGARD GRAHAM PETER sold $4.02M worth of Exact Sciences Corporation (NASDAQ:EXAS) or 58,000 shs. The insider Elliott Jeffrey Thomas sold 90,909 shs worth $7.17 million. Conroy Kevin T had sold 304,397 shs worth $24.74 million.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

A total of 6 analysts rate Exact Sciences (NASDAQ:EXAS) as follows: 6 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NASDAQ:EXAS) has 10 ratings reports on 15 Mar 2019 according to StockzIntelligence. On Friday, February 22 BTIG Research maintained Exact Sciences Corporation (NASDAQ:EXAS) rating. BTIG Research has “Buy” rating and $110 target. In Thursday, February 21 report Robert W. Baird maintained the stock with “Buy” rating. On Friday, February 22 the stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Canaccord Genuity. On Friday, February 22 the firm has “Buy” rating by UBS given. On Wednesday, October 31 Jefferies maintained Exact Sciences Corporation (NASDAQ:EXAS) with “Buy” rating. In Thursday, November 29 report UBS maintained it with “Buy” rating and $10000 target. On Friday, February 22 the stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Craig Hallum.

For more Exact Sciences Corporation (NASDAQ:EXAS) news published recently go to: , Nasdaq.com, Seekingalpha.com, Benzinga.com or Nasdaq.com. The titles are as follows: “7 Strong Buy Stocks the Street Loves – Yahoo Finance” published on March 01, 2019, “Look Under The Hood: IWB Has 10% Upside – Nasdaq” on March 07, 2019, “Goldman sees 31% upside in Exact Sciences in premarket analyst action – Seeking Alpha” with a publish date: February 26, 2019, “The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings (Feb. 17-23) – Benzinga” and the last “Why Guardant Health Is the Best Healthcare Stock You’ve Never Heard Of – Nasdaq” with publication date: March 12, 2019.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.